Methodologies

Criteria

Methodologies should present a new experimental or computational method, test or procedure. The method described may either be completely new, or may offer a better version of an existing method. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.

 

Submission process

Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The submitting author takes responsibility for the article during submission and peer review.

 

To facilitate rapid publication and to minimize administrative costs, we prefers online submission.

 

FILE FORMATS

The following word processor file formats are acceptable for the main manuscript document:

  • Microsoft word (DOC, DOCX)
  • Rich text format (RTF)
  • Portable document format (PDF)

 

Length of article

Research articles should be approximately 3000 words with 50 references.

Overview of manuscript sections for Research articles

Manuscripts for Research articles submitted to Biomedical Research and Therapy should be divided into the following sections (in this order):

� Title page

� Abstract

� Keywords

� Introduction

� Materials-Methods

� Results

� Discussion

� Conclusions

� List of abbreviations used (if any)

� Competing interests

� Acknowledgements

� Endnotes

� References

� Illustrations and figures (if any)

� Tables and captions (if any)

 

The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets and include the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116]. The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).

Title page

The title page should:

� provide the title of the article

� list the full names, institutional addresses and email addresses for all authors

� indicate the corresponding author

Please note:� abbreviations within the title should be avoided

Abstract

A short, unstructured, single paragraph summary, no more than 350 words, of the major points raised, making evident the key work highlighted in the article.

Keywords

Three to ten keywords representing the main content of the article.

Introduction

This section should put the work in adequate context and should be comprehensible to non-experts some of who may not have a scientific or technological background.

Materials-Methods

This section should put the methods and used materials in your study. All sources of chemicals, cell lines were be included in this part. All methods related to preclinical studies as well as clinical studies must be approved by ethical committee. The name of ethical committee should be included in the methods.

Results

Results should be clearly presented with experiments performed in the methods. These results with many data should be summarized in the tables or graphs.

Discussion

All explanations and result analysis should be included in this part. In the last paragraph, author(s) should suggest the potential of the study.

Conclusions

This should state clearly the main conclusions of the review and give a clear explanation of their importance and relevance.

 

LIST OF ABBREVIATIONS

If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations can be provided, which should precede the competing interests and authors' contributions.

 

COMPETING INTERESTS

A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors must disclose any financial competing interests; they should also reveal any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.

Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.

When completing your declaration, please consider the following questions:

Financial competing interests

� In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.

� Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.

� Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.

� Do you have any other financial competing interests? If so, please specify.

 

Non-financial competing interests

Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.

If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss it with the editorial office.

 

ACKNOWLEDGEMENTS

Please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship.

Please also include the source(s) of funding for each author, and for the manuscript preparation. Authors must describe the role of the funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

Please also acknowledge anyone who contributed materials essential for the study.

If a language editor has made significant revision of the manuscript, we recommend that you acknowledge the editor by name, where possible. The role of a scientific (medical) writer must be included in the acknowledgements section, including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.'

Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.

 

ENDNOTES

Endnotes should be designated within the text using a superscript lowercase letter and all notes (along with their corresponding letter) should be included in the Endnotes section. Please format this section in a paragraph rather than a list.

 

REFERENCES

Literature citations in the text should indicate the author's surname with the year of publication in parentheses, e.g. Carlin (1992); Brooks and Carlin (1992).

If there are more than two authors, only the first should be named, followed by "et al."

References at the end of the paper should be listed in alphabetical order by the first author's name.

If there is more than one work by the same author or team of authors in the same year, a, b, etc. is added to the year both in the text and in the list of references.

Journal papers: name(s) and initial(s) of all authors; year; full title; journal title abbreviated in accordance with international practice; volume number; first and last page numbers.

 

Example:

Nakashima K, Yamada L, Satou Y, Azuma J, Satoh N (2004)The evolutionary origin of animal cellulose synthase. Dev Genes Evol 214: 81-88

Single contribution in a book: name(s) and initial(s) of all authors; year; title of article; editor(s); title of book; edition; volume number; publisher; place of publication; page numbers

Example:

Sanger JW (1977) Nontubulin molecules in the spindle. In: Little M, Paweletz N, Petzelt C, Ponstingl H, Schroeter D, Zimmermann H-P (eds) Mitosis facts and questions. Springer, Berlin Heidelberg New York, pp 98-113

Book: name and initial(s) of all authors; year; title; publisher; place of publication

Example: Hall BK (1999) The Neural Crest in Development and Evolution. Springer, Berlin Heidelberg New York

Agency publication: Council of biology editors style manual. CBE style manual committee. 5th ed. Bethesda, MD: Council of Biology Editors; 1983.

Web pages:

1. Article by DOI (with page numbers): Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med 78:74–80. doi: 10.1007/s001090000086

2. Article by DOI (before issue publication with page numbers): Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med (in press). doi: 10.1007/s001090000086

3. Article in electronic journal by DOI (no paginated version): Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. Dig J Mol Med. doi: 10.1007/s801090000086

4. Online document: Doe J (1999) Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry.Available via DIALOG. http://www.rsc.org/dose/title of subordinate document. Cited 15 Jan 1999

5. Online database: Healthwise Knowledgebase (1998) US Pharmacopeia, Rockville. http://www.healthwise.org. Cited 21 Sept 1998

6. Supplementary material/private homepage: Doe J (2000) Title of supplementary material. http://www.privatehomepage.com. Cited 22 Feb 2000

7. University site: Doe J (1999) Title of preprint. http://www.uni-heidelberg.de/mydata.html. Cited 25 Dec 1999

8. FTP site Doe J (1999) Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt. Cited 12 Nov 1999

9. Organization site: ISSN International Centre (1999) Global ISSN database. http://www.issn.org. Cited 20 Feb 2000

Unpublished results may be cited in the text as personal communications.

However, in this case the final version of the manuscript must be accompanied by a note of consent signed by each author quoted.

Style files are available for use with popular bibliographic management software: Endnote Style file (click here to download and add to style folder in your Endnote program)

 

PREPARING ILLUSTRATIONS AND FIGURES

Illustrations should be provided as separate files, not embedded in the text file.

Each figure should include a single illustration and should fit on a single page in portrait format.

If a figure consists of separate parts, it is important that a single composite illustration file be submitted which contains all parts of the figure.

There is no charge for the use of color figures.

Formats

The following file formats can be accepted:

� PDF (preferred format for diagrams)

� DOCX/DOC (single page only)

� PPTX/PPT (single slide only)

� EPS

� PNG (preferred format for photos or images)

� TIFF

� JPEG

� BMP

Biomedical Research & Therapy will edit all figures supplied by the author. For this reason it is especially important that authors should supply figures in vector form, to facilitate such editing.

Figure legends

The legends should be included in the main manuscript text file at the end of the document, rather than being a part of the figure file.

For each figure, the following information should be provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up to 300 words.

Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures or tables that have previously been published elsewhere.

Preparing tables

Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.).

Tables should also have a title (above the table) that summarizes the whole table; it should be no longer than 15 words. Detailed legends may then follow, but they should be concise.

Tables should always be cited in text in consecutive numerical order. Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in A4 portrait or landscape format.

These will be typeset and displayed in the final published form of the article. Such tables should be formatted using the 'Table object' in a word processing program to ensure that columns of data are kept aligned when the file is sent electronically for review; this will not always be the case if columns are generated by simply using tabs to separate text. Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell display as black lines. Commas should not be used to indicate numerical values. Color and shading may not be used; parts of the table can be highlighted using symbols or bold text, the meaning of which should be explained in a table legend.

Tables should not be embedded as figures or spreadsheet files. Larger datasets or tables too wide for a landscape page can be uploaded separately as additional files.

Additional files will not be displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the author.

Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or comma separated values (.csv).

As with all files, please use the standard file extensions.